QR Kod

Omalizumab and cancer risk: Current evidence in allergic asthma, chronic urticaria, and chronic rhinosinusitis with nasal polyps

Omalizumab is a biological drug targeting circulating IgE, approved for use in allergic asthma, chronic spontaneous urticaria, and recently for chronic rhinosinusitis with nasal polyps, with good efficacy in all these settings. Some concerns about omalizumab safety have been raised as its use has be...

Ful tanımlama

Kaydedildi:
Asıl Yazarlar: Diego Bagnasco, MD, PhD, Rikki Frank Canevari, MD, Stefano Del Giacco, MD, Silvia Ferrucci, MD, Paolo Pigatto, MD, Paolo Castelnuovo, MD, Gian Luigi Marseglia, MD, Arzu Didem Yalcin, MD, Girolamo Pelaia, MD, Giorgio Walter Canonica, MD
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Elsevier 2022-12-01
Seri Bilgileri:World Allergy Organization Journal
Konular:
Severe asthma
Omalizumab
Cancer
Anti IgE
Monoclonal antibodies
Online Erişim:http://www.sciencedirect.com/science/article/pii/S1939455122000977
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller